Keywords: Ischemic stroke, Markets, Research, Activase

Ischemic stroke continues to be a graveyard for drug development, says Decision Resources, but market will grow to $450 million in 2018

Article | 18 November 2009

Print This

Sales of agents to treat acute ischemic stroke will remain relatively flat over the next decade, increasing from $360 million in 2008 ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in